



NDA 209241/S-016

**SUPPLEMENT APPROVAL/
FULFILLMENT OF POSTMARKETING REQUIREMENTS**

Neurocrine Biosciences, Inc.
Attention: Kristine Kim
Sr. Director, Regulatory Affairs
12780 El Camino Real
San Diego, CA 92130

Dear Ms. Kim:

Please refer to your supplemental new drug application (sNDA) dated and received August 29, 2019, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ingrezza (valbenazine) capsules.

This Prior Approval supplemental new drug application provides for revisions to Highlights, section 2 (Dosage and Administration), section 7 (Drug Interactions), section 8.6 (CYP2D6 Poor Metabolizers), section 8.8 (Renal Impairment), and section 12.3 (Pharmacokinetics) based upon results of your postmarketing requirement studies.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Patient Package Insert) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have received your submissions dated August 17, 2018, and August 29, 2019, containing the final reports for the following postmarketing requirements listed in the April 11, 2017, approval letter.

- 3177-1 Conduct an in vitro study to assess the induction potential of NBI-136110 on CYP2B6 enzyme.
- 3177-2 Conduct a pharmacokinetic trial to quantify the impact of CYP2D6 inhibition on the exposures of the parent compound and major metabolites, either in the presence of a strong CYP2D6 inhibitor or in subjects who are CYP2D6 poor metabolizers (PMs).
- 3177-3 Conduct a pharmacokinetic trial to assess exposure differences of the parent compound and major metabolites in patients with severe renal impairment and matching subjects with normal renal function receiving the same dose."

We have reviewed your submissions and conclude that the above requirements were fulfilled.

We remind you that there are postmarketing commitments and a postmarketing requirement listed in the April 11, 2017, approval letter that are still open.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, email Simran Parihar, PharmD, at simran.parihar@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tiffany R. Farchione, MD
Director (Acting)
Division of Psychiatry
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TIFFANY R FARCHIONE
04/09/2020 01:54:49 PM